Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA

Pharmacoeconomics. 2020 Jan;38(1):123. doi: 10.1007/s40273-019-00857-7.

Authors

Elizabeth Wehler¹, Natalie Boytsov², Claudia Nicolay³, Oscar Herrera-Restrepo⁴, Stacey Kowal⁴

Affiliations

¹ IQVIA, 1 IMS Drive, Plymouth Meeting, PA, 19462, USA. beth.wehler@iqvia.com.
² Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
³ Lilly Deutschland GmbH, Bad Homburg, Germany.
⁴ IQVIA, 3110 Fairview Park Drive, Falls Church, VA, 22042, USA.

Abstract

Due to a single error in the annual cost of sarilumab the following needs to be corrected in the article.

Publication types

Published Erratum